Heptares Therapeutics
Hironoshin Nomura has extensive work experience in the financial sector. Hironoshin is currently working at Sosei Heptares, where they serve as the Chief Financial Officer since March 2022. Prior to this role, they held a position in IR & Corporate Strategy at Sosei Heptares from September 2020 to March 2022.
Before joining Sosei Heptares, Nomura worked at Mizuho Bank as a Senior Analyst from January 2015 to August 2020. Prior to that, they worked as a Consultant at Mitsubishi Research Institute from April 2009 to December 2014.
Hironoshin Nomura pursued their education from 2003 to 2009 at Tohoku University, where they obtained a Master's degree in Pharmacy.
This person is not in any offices
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.